Tesaro Inc (NASDAQ: TSRO) enjoyed its best summer ever last year, but lately, this biotech has had a case of the blues. Following a peak in February, the stock has lost more than a quarter of its value.Despite the recent slide, investors should remain braced for further downside. The company's recently launched cancer therapy has plenty of potential, but its success is far from certain.